Aquyre Biosciences has recognised Lung Cancer Awareness Month by reaching a milestone of over 400 lung biopsy procedures completed using the CelTivity microscopy system.
CelTivity provides an easy-to-read image, like a PET scan for cells, making cancer cells glow. Physicians found that by using CelTivity they had a significantly higher rate of cancer detection (96%), compared to traditional methods (57%). By using CelTivity, physicians can be more confident in their findings and quickly provide diagnosis guidance to patients.
CelTivity is the only microscopic system on the market to provide physicians with a non-destructive Rapid On-Site Evaluation (ROSE) of a biopsy for both fine needle aspiration (FNA) and tissue. Powered by proprietary technologies, including Dynamic Cell Imaging (DCI), CelTivity analyses the entire biopsy’s intracellular and metabolic activity. This activity is then presented in a heatmap, making results easy to interpret. The two-minute microscopic evaluation does not require any cutting or staining. As a result, the same tissue evaluated for adequacy is sent unchanged to final pathology for final diagnosis and next generation sequencing (NGS).
The image above shows lung cancer detected using CelTivity microscope and virtual stain options. Looking at PET View (left) and Histo View (right) shows significant cell abnormalities on the right of each image.
“We are thrilled to have quickly reached such a milestone and accelerate the accurate diagnosis of patients,” said Aquyre Biosciences’ CEO Bertrand Le Conte De Poly. “This rapid adoption is testament to the technology and speaks to the future of diagnostics and advanced treatment options. We look forward to being on the forefront of that.”
To learn more about Aquyre Biosciences and CelTivity visit www.aquyre.com.